GlassScriptPhysician profile
Jaime Lee
NPI 1407352925
$17,944.46
in general payments reported to CMS, 2019-2025
11 companies · $2,253 in 2025
The $2,253 reported for 2025 was more than what 85% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,772 · 2022: $4,557 · 2023: $915 · 2024: $8,447 · 2025: $2,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,250 · Travel and Lodging: $3,663 · Food and Beverage: $2,644 · Education: $58.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,250.00 |
| Travel and Lodging | $3,662.50 |
| Food and Beverage | $2,643.84 |
| Education | $58.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $12,980.95 | 2021-2025 | Ankle Hindfoot Nailing System, Truelok, Truelok System |
| Pylant Medical | $1,648.82 | 2023-2025 | |
| Stryker Corporation | $1,492.99 | 2021-2025 | Citrefix, Prostep, Ortholoc 2 Lapifuse |
| Arthrex, INC. | $836.35 | 2024-2025 | |
| In2bones USA, LLC | $539.96 | 2021 | |
| Integra Lifesciences Corporation | $179.52 | 2021-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Cerapedics INC. | $140.64 | 2023 | I-Factor Peptide Enhanced Bone Graft |
| Smith+Nephew, INC. | $68.61 | 2025 | Collagenase Santyl, Regranex |
| Biocomposites INC | $30.11 | 2025 | Stimulan |
| Bioventus LLC | $13.44 | 2022 | |
| Paragon 28, INC. | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.